111 related articles for article (PubMed ID: 35577684)
1. Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan.
Namiki T; Komine-Aizawa S; Takada K; Takano C; Trinh QD; Hayakawa S
J Infect Chemother; 2022 Aug; 28(8):1220-1224. PubMed ID: 35577684
[TBL] [Abstract][Full Text] [Related]
2. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study.
Urakawa R; Isomura ET; Matsunaga K; Kubota K; Ike M
BMC Infect Dis; 2022 Feb; 22(1):179. PubMed ID: 35197017
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.
Lee DY; Kang DY; Kim E; Lee SJ; Baek JH; Lee JS; Park MY; Im JH
Medicine (Baltimore); 2023 Mar; 102(11):e33236. PubMed ID: 36930126
[TBL] [Abstract][Full Text] [Related]
4. Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.
Ughi N; Del Gaudio F; Dicuonzo A; Orso M; Micheloni G; Puoti M; Pani A; Scaglione F; Zoppini L; Rossetti C; Epis OM; Bellavia G; Giroldi S; Moreno M; Bosio M
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7985-7996. PubMed ID: 34982462
[TBL] [Abstract][Full Text] [Related]
5. The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.
Jubishi D; Okamoto K; Hamada K; Ishii T; Hashimoto H; Shinohara T; Yamashita M; Wakimoto Y; Otani A; Hisasue N; Ikeda M; Harada S; Okugawa S; Moriya K; Yanagimoto S
Hum Vaccin Immunother; 2022 Nov; 18(5):2048559. PubMed ID: 35333697
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
7. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Naito T; Tsuchida N; Kusunoki S; Kaneko Y; Tobita M; Hori S; Ito S
Expert Rev Vaccines; 2022 Sep; 21(9):1319-1329. PubMed ID: 35763290
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study.
Ripabelli G; Tamburro M; Buccieri N; Adesso C; Caggiano V; Cannizzaro F; Di Palma MA; Mantuano G; Montemitro VG; Natale A; Rodio L; Sammarco ML
J Community Health; 2022 Apr; 47(2):211-225. PubMed ID: 34628568
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
12. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. The association of three doses of the BNT162b2 mRNA vaccine with abnormal bleeding and an irregular menstrual cycle among premenopausal females: A single institute observation study.
Namiki T; Komine-Aizawa S; Takada K; Takano C; Trinh QD; Hayakawa S
J Obstet Gynaecol Res; 2022 Nov; 48(11):2903-2910. PubMed ID: 36319205
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
19. The Impact of the Emotional Disposition of Healthcare Workers on the Expression of Adverse Events after Primary Vaccination against SARS-CoV-2.
Sauserienė J; Serapinas D; Liseckienė I; Budrevičiūtė A; Vaičiūnienė R; Gradauskienė B; Tkačiovaitė E; Sakalauskaitė S; Valius L
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541110
[No Abstract] [Full Text] [Related]
20. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
